This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Lupus Anticoagulant and Anticardiolipin Antibodies in Serum of Patients Treated With Risperidone

Miguel Schwartz, Maria Kormilachev, Mina Kushnir, Boaz Weller, Marina Rochas, and Elias Toubi

Published: May 14, 2009

Article Abstract

Letter to the Editor

Sir: In recent years, several studies reported an increasedrate of cerebrovascular events in patients treated with risperidone.In April 2005, the U.S. Food and Drug Administration issueda health advisory warning concerning an increased risk ofdeath among patients with dementia who were treated withatypical antipsychotic agents.

Risperidone is a second-generation antipsychotic agent thatreportedly increases the blood level of glucose and alterschanges in lipid profiles.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 70

Quick Links: Psychiatry

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...